Skip to main content
. Author manuscript; available in PMC: 2025 Aug 25.
Published in final edited form as: J Pharmacol Exp Ther. 2024 Nov 22;392(1):100034. doi: 10.1124/jpet.124.002424

Fig. 4.

Fig. 4.

Combination treatment of enzalutamide and metformin did not attenuate LuCaP35CR tumor growth in vivo. (A) Tumor growth curves of LuCaP35CR xenografts (mean ± SD; n = 4 mice per group). (B) Measurement of tumor weight immediately after harvest. (C) Images of LuCaP35CR tumors at the end of the study. (D) Measurement of mouse body weight throughout the study.